Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: CEBPA

Gene summary for CEBPA

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

CEBPA

Gene ID

1050

Gene nameCCAAT enhancer binding protein alpha
Gene AliasC/EBP-alpha
Cytomap19q13.11
Gene Typeprotein-coding
GO ID

GO:0000003

UniProtAcc

P49715


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
1050CEBPALZE4THumanEsophagusESCC1.37e-025.32e-020.0811
1050CEBPALZE24THumanEsophagusESCC2.83e-079.25e-020.0596
1050CEBPALZE21THumanEsophagusESCC1.94e-031.47e-010.0655
1050CEBPAP1T-EHumanEsophagusESCC3.11e-065.20e-010.0875
1050CEBPAP2T-EHumanEsophagusESCC2.41e-142.09e-010.1177
1050CEBPAP4T-EHumanEsophagusESCC9.29e-071.48e-010.1323
1050CEBPAP5T-EHumanEsophagusESCC4.62e-023.08e-020.1327
1050CEBPAP8T-EHumanEsophagusESCC4.63e-161.82e-010.0889
1050CEBPAP9T-EHumanEsophagusESCC1.92e-133.61e-010.1131
1050CEBPAP10T-EHumanEsophagusESCC2.90e-193.66e-010.116
1050CEBPAP11T-EHumanEsophagusESCC1.82e-092.16e-010.1426
1050CEBPAP12T-EHumanEsophagusESCC1.58e-173.30e-010.1122
1050CEBPAP15T-EHumanEsophagusESCC4.95e-215.47e-010.1149
1050CEBPAP16T-EHumanEsophagusESCC4.76e-045.12e-020.1153
1050CEBPAP20T-EHumanEsophagusESCC6.65e-081.23e-010.1124
1050CEBPAP22T-EHumanEsophagusESCC1.12e-182.37e-010.1236
1050CEBPAP23T-EHumanEsophagusESCC9.10e-142.34e-010.108
1050CEBPAP26T-EHumanEsophagusESCC2.70e-141.38e-010.1276
1050CEBPAP27T-EHumanEsophagusESCC2.04e-027.49e-020.1055
1050CEBPAP28T-EHumanEsophagusESCC2.84e-122.53e-010.1149
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0010498111EsophagusESCCproteasomal protein catabolic process369/8552490/187231.13e-411.80e-38369
GO:0043161111EsophagusESCCproteasome-mediated ubiquitin-dependent protein catabolic process312/8552412/187233.53e-364.48e-33312
GO:0042176111EsophagusESCCregulation of protein catabolic process280/8552391/187238.65e-262.39e-23280
GO:0006091110EsophagusESCCgeneration of precursor metabolites and energy331/8552490/187233.86e-238.45e-21331
GO:0009896111EsophagusESCCpositive regulation of catabolic process332/8552492/187234.36e-239.22e-21332
GO:0031331111EsophagusESCCpositive regulation of cellular catabolic process292/8552427/187238.67e-221.53e-19292
GO:1903362111EsophagusESCCregulation of cellular protein catabolic process188/8552255/187235.12e-206.62e-18188
GO:0045862111EsophagusESCCpositive regulation of proteolysis256/8552372/187237.88e-209.43e-18256
GO:1903050111EsophagusESCCregulation of proteolysis involved in cellular protein catabolic process163/8552221/187231.44e-171.27e-15163
GO:0061136111EsophagusESCCregulation of proteasomal protein catabolic process142/8552187/187232.40e-172.00e-15142
GO:0045732111EsophagusESCCpositive regulation of protein catabolic process167/8552231/187231.47e-161.14e-14167
GO:0032434111EsophagusESCCregulation of proteasomal ubiquitin-dependent protein catabolic process107/8552134/187234.06e-162.93e-14107
GO:000170119EsophagusESCCin utero embryonic development243/8552367/187231.00e-156.86e-14243
GO:2000058111EsophagusESCCregulation of ubiquitin-dependent protein catabolic process125/8552164/187231.17e-157.76e-14125
GO:1903364111EsophagusESCCpositive regulation of cellular protein catabolic process117/8552155/187233.25e-141.66e-12117
GO:1901800110EsophagusESCCpositive regulation of proteasomal protein catabolic process91/8552114/187236.74e-143.34e-1291
GO:1903052110EsophagusESCCpositive regulation of proteolysis involved in cellular protein catabolic process101/8552133/187239.58e-134.19e-11101
GO:0010563111EsophagusESCCnegative regulation of phosphorus metabolic process274/8552442/187232.32e-129.41e-11274
GO:0045936111EsophagusESCCnegative regulation of phosphate metabolic process273/8552441/187233.18e-121.25e-10273
GO:0048732111EsophagusESCCgland development269/8552436/187237.81e-122.95e-10269
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04932210EsophagusESCCNon-alcoholic fatty liver disease122/4205155/84655.69e-141.59e-128.14e-13122
hsa052215EsophagusESCCAcute myeloid leukemia49/420567/84657.43e-053.07e-041.57e-0449
hsa052028EsophagusESCCTranscriptional misregulation in cancer116/4205193/84652.08e-035.95e-033.05e-03116
hsa0493238EsophagusESCCNon-alcoholic fatty liver disease122/4205155/84655.69e-141.59e-128.14e-13122
hsa0522113EsophagusESCCAcute myeloid leukemia49/420567/84657.43e-053.07e-041.57e-0449
hsa0520213EsophagusESCCTranscriptional misregulation in cancer116/4205193/84652.08e-035.95e-033.05e-03116
hsa0493222LiverCirrhoticNon-alcoholic fatty liver disease106/2530155/84652.16e-232.40e-211.48e-21106
hsa0493232LiverCirrhoticNon-alcoholic fatty liver disease106/2530155/84652.16e-232.40e-211.48e-21106
hsa0493242LiverHCCNon-alcoholic fatty liver disease124/4020155/84654.54e-172.54e-151.41e-15124
hsa05221LiverHCCAcute myeloid leukemia41/402067/84651.64e-023.90e-022.17e-0241
hsa0493252LiverHCCNon-alcoholic fatty liver disease124/4020155/84654.54e-172.54e-151.41e-15124
hsa052211LiverHCCAcute myeloid leukemia41/402067/84651.64e-023.90e-022.17e-0241
hsa0493228Oral cavityOSCCNon-alcoholic fatty liver disease124/3704155/84651.22e-201.37e-186.96e-19124
hsa052214Oral cavityOSCCAcute myeloid leukemia42/370467/84651.34e-033.75e-031.91e-0342
hsa04932112Oral cavityOSCCNon-alcoholic fatty liver disease124/3704155/84651.22e-201.37e-186.96e-19124
hsa0522112Oral cavityOSCCAcute myeloid leukemia42/370467/84651.34e-033.75e-031.91e-0342
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
CEBPAM2MACEndometriumADJPSAP,GYG1,TREM2, etc.2.66e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAINMONEndometriumADJPSAP,GYG1,TREM2, etc.7.69e-02The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAM2MACEndometriumAEHPSAP,GYG1,TREM2, etc.2.79e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAINMONEndometriumAEHPSAP,GYG1,TREM2, etc.6.26e-02The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAM2MACEndometriumEECPSAP,GYG1,TREM2, etc.3.49e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAINMONEndometriumEECPSAP,GYG1,TREM2, etc.5.59e-02The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAM2MACEndometriumHealthyPSAP,GYG1,TREM2, etc.4.51e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAINMONEndometriumHealthyPSAP,GYG1,TREM2, etc.6.97e-02The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAHEPLiverHCCSNORA76,FSTL5,FAM115A, etc.8.20e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
CEBPAM2MACLungMIACAC124016.1,PSAP,CTSD, etc.3.25e-01The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 2 3 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
CEBPASNVMissense_Mutationrs780335632c.803N>Tp.Gly268Valp.G268VP49715protein_codingtolerated(0.09)benign(0.001)TCGA-C5-A3HL-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
CEBPASNVMissense_Mutationc.840N>Cp.Lys280Asnp.K280NP49715protein_codingdeleterious(0)probably_damaging(0.92)TCGA-DR-A0ZM-01Cervixcervical & endocervical cancerFemale<65III/IVUnspecificCisplatinSD
CEBPASNVMissense_Mutationc.1015C>Tp.Arg339Trpp.R339WP49715protein_codingdeleterious(0)probably_damaging(0.997)TCGA-JW-A5VL-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
CEBPASNVMissense_Mutationc.947A>Cp.Glu316Alap.E316AP49715protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AA-3663-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
CEBPASNVMissense_Mutationnovelc.955A>Gp.Ser319Glyp.S319GP49715protein_codingtolerated(0.05)benign(0.171)TCGA-AA-A01P-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownPD
CEBPASNVMissense_Mutationc.1073N>Tp.Ala358Valp.A358VP49715protein_codingdeleterious(0.01)possibly_damaging(0.788)TCGA-EC-A1QX-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIChemotherapycyclophosphamidePD
CEBPASNVMissense_Mutationc.866N>Ap.Arg289Hisp.R289HP49715protein_codingdeleterious(0)probably_damaging(0.999)TCGA-VQ-A8PP-01Stomachstomach adenocarcinomaMale>=65III/IVChemotherapyfluorouracilPD
CEBPASNVMissense_Mutationnovelc.869N>Tp.Glu290Valp.E290VP49715protein_codingdeleterious(0)probably_damaging(0.993)TCGA-VQ-A91K-01Stomachstomach adenocarcinomaMale>=65III/IVChemotherapyfluorouracilCR
Page: 1 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
1050CEBPATRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLEOICR-942926167872
1050CEBPATRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLEN/A20038735,26601784,19171880,22814295,25241285,23521373
Page: 1